- Home
- MVBF vs ACIU Comparison
MVBF vs ACIU Comparison
Compare MVBF & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MVBF | ACIU |
|---|---|---|
| Founded | 1997 | 2003 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 372.5M | 244.3M |
| IPO Year | 2004 | 2015 |
Fundamental Metrics
Financial Performance| Metric | MVBF | ACIU |
|---|---|---|
| Price | $29.41 | $2.51 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 2 |
| Target Price | ★ $29.50 | $10.00 |
| AVG Volume (30 Days) | 55.2K | ★ 305.3K |
| Earning Date | 04-29-2026 | 05-12-2026 |
| Dividend Yield | ★ 2.63% | N/A |
| EPS Growth | ★ 34.64 | N/A |
| EPS | ★ 0.39 | N/A |
| Revenue | ★ $3,400,000.00 | N/A |
| Revenue This Year | $1.70 | $706.75 |
| Revenue Next Year | $13.59 | $321.13 |
| P/E Ratio | $76.51 | ★ N/A |
| Revenue Growth | ★ 51.92 | N/A |
| 52 Week Low | $22.14 | $1.94 |
| 52 Week High | $29.89 | $4.00 |
Technical Indicators
Market Signals| Indicator | MVBF | ACIU |
|---|---|---|
| Relative Strength Index (RSI) | 66.85 | 48.60 |
| Support Level | $24.83 | N/A |
| Resistance Level | N/A | $3.92 |
| Average True Range (ATR) | 1.02 | 0.14 |
| MACD | 0.13 | 0.03 |
| Stochastic Oscillator | 79.94 | 63.09 |
Price Performance
Historical ComparisonAbout MVBF MVB Financial Corp.
MVB Financial Corp is a financial holding company. The company provides a wide range of business activities through the Bank, commercial and retail banking services, as well as Fintech banking. It has three reportable segments: CoRe Banking, Mortgage Banking, and Financial Holding Company. The majority of its revenue is generated from the CoRe Banking segment, which includes its Fintech division, represents banking products and services offered to customers by the Bank, loans and deposits accounts. Revenue from banking activities consists of interest earned on loans and investment securities and service charges on deposit accounts.
About ACIU AC Immune SA
AC Immune SA is a clinical stage biopharmaceutical company advancing a portfolio of programs strategically focused on pioneering Precision Medicine for neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company has one segment. The company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.